AIM: To evaluate the efficacy, pharmacokinetic (PK) profile and tolerability of subcutaneous (s.c.). exendin 9-39 (Ex-9) injection in patients with post-bariatric hypoglycaemia (PBH). METHODS:Nine women who had recurrent symptomatic hypoglycaemia after undergoing Roux-en-Y gastric bypass were enrolled in this 2-part, single-blind, single-ascending-dose study. In Part 1, a single participant underwent equimolar low-dose intravenous (i.v.) vs s.c. Ex-9 administration; in Part 2, 8 participants were administered single ascending doses of s.c. Ex-9 during an oral glucose tolerance test (OGTT). Glycaemic, hormonal, PK and symptomatic responses were compared with those obtained during the baseline OGTT. RESULTS: Although an exposure-response relationship was observed, all doses effectively prevented hyperinsulinaemic hypoglycaemia and improved associated symptoms. On average, the postprandial glucose nadir was increased by 66%, peak insulin was reduced by 57%, and neuroglycopenic symptoms were reduced by 80%. All doses were well tolerated with no treatment-emergent adverse events observed. CONCLUSIONS: Injection s.c. of Ex-9 appears to represent a safe, effective and targeted therapeutic approach for treatment of PBH. Further investigation involving multiple doses with chronic dosing is warranted.
RCT Entities:
AIM: To evaluate the efficacy, pharmacokinetic (PK) profile and tolerability of subcutaneous (s.c.). exendin 9-39 (Ex-9) injection in patients with post-bariatric hypoglycaemia (PBH). METHODS: Nine women who had recurrent symptomatic hypoglycaemia after undergoing Roux-en-Y gastric bypass were enrolled in this 2-part, single-blind, single-ascending-dose study. In Part 1, a single participant underwent equimolar low-dose intravenous (i.v.) vs s.c. Ex-9 administration; in Part 2, 8 participants were administered single ascending doses of s.c. Ex-9 during an oral glucose tolerance test (OGTT). Glycaemic, hormonal, PK and symptomatic responses were compared with those obtained during the baseline OGTT. RESULTS: Although an exposure-response relationship was observed, all doses effectively prevented hyperinsulinaemic hypoglycaemia and improved associated symptoms. On average, the postprandial glucose nadir was increased by 66%, peak insulin was reduced by 57%, and neuroglycopenic symptoms were reduced by 80%. All doses were well tolerated with no treatment-emergent adverse events observed. CONCLUSIONS: Injection s.c. of Ex-9 appears to represent a safe, effective and targeted therapeutic approach for treatment of PBH. Further investigation involving multiple doses with chronic dosing is warranted.
Authors: Christopher M Mulla; Allison B Goldfine; Jonathan M Dreyfuss; Sander Houten; Hui Pan; David M Pober; Nicolai J Wewer Albrechtsen; Maria S Svane; Julie B Schmidt; Jens Juul Holst; Colleen M Craig; Tracey L McLaughlin; Mary-Elizabeth Patti Journal: Obes Surg Date: 2019-07 Impact factor: 4.129
Authors: Jiang Wang; Brian P Cary; Peyton D Beyer; Samuel H Gellman; Daniel J Weix Journal: Angew Chem Int Ed Engl Date: 2019-07-30 Impact factor: 15.336
Authors: Brian P Cary; Giuseppe Deganutti; Peishen Zhao; Tin T Truong; Sarah J Piper; Xinyu Liu; Matthew J Belousoff; Radostin Danev; Patrick M Sexton; Denise Wootten; Samuel H Gellman Journal: Nat Chem Biol Date: 2021-12-22 Impact factor: 16.174
Authors: Christopher M Mulla; Stamatina Zavitsanou; Alejandro Jose Laguna Sanz; David Pober; Lauren Richardson; Pamela Walcott; Ipsa Arora; Brett Newswanger; Martin J Cummins; Steve J Prestrelski; Francis J Doyle; Eyal Dassau; Mary Elizabeth Patti Journal: J Clin Endocrinol Metab Date: 2020-04-01 Impact factor: 5.958
Authors: Marloes Emous; Merel van den Broek; Ragnhild B Wijma; Loek J M de Heide; Gertjan van Dijk; Anke Laskewitz; Erik Totté; Bruce H R Wolffenbuttel; André P van Beek Journal: Endocr Connect Date: 2019-07 Impact factor: 3.335
Authors: Simon S Evers; Ki-Suk Kim; Nadejda Bozadjieva; Alfor G Lewis; Diana Farris; Matthew J Sorensen; Youngsoo Kim; Steven E Whitesall; Robert T Kennedy; Daniel E Michele; Randy J Seeley; Darleen A Sandoval Journal: Mol Metab Date: 2019-12-24 Impact factor: 7.422
Authors: Colleen M Craig; Helen Margaret Lawler; Clare Jung Eun Lee; Marilyn Tan; Dawn Belt Davis; Jenny Tong; Michele Glodowski; Elisa Rogowitz; Rowan Karaman; Tracey L McLaughlin; Lisa Porter Journal: J Clin Endocrinol Metab Date: 2021-07-13 Impact factor: 5.958